Speakers - Sachs Associates
Speakers - Sachs Associates
Speakers - Sachs Associates
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
CONTACT<br />
Richard Jones<br />
Chief Financial Officer<br />
ADDRESS<br />
Shield Therapeutics,<br />
Rotterdam House,<br />
116 Quayside,<br />
Newcastle upon Tyne<br />
NE1 3DY<br />
TELEPHONE<br />
+44 (0) 191 206 4046<br />
FAX<br />
+44 (0) 870 458 6523<br />
EMAIL<br />
info@shieldtherapeutics.com<br />
YEAR FOUNDED<br />
2008<br />
Shield Therapeutics<br />
www.shieldtherapeutics.com<br />
COMPANY PROFILE<br />
Shield Therapeutics, founded in 2008, is an independent specialty pharmaceutical company focused on the<br />
development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address<br />
areas of high unmet medical need. Shield is currently conducting two global pivotal Phase 3 studies of its lead<br />
asset, ST10, for the treatment of iron deficiency anaemia associated with Ulcerative Colitis and Crohn’s disease<br />
and is now also commencing a Phase 3 study of ST10 for the treatment of iron deficiency anaemia in patients<br />
with chronic kidney disease.<br />
MANAGEMENT<br />
Carl Sterritt, CEO<br />
Richard Jones, CFO<br />
t back :: next u<br />
WELCOME PHARMA LICENSING GROUPS<br />
SPEAKERS<br />
PRESENTING COMPANIES SUPPORTING ORGANISATIONS<br />
ORGANISERS
Change language